Introduction {#s1}
============

The methamphetamine epidemic in the United States has been widely characterised as a significant public health concern. Methamphetamine is a psychostimulant of the phenethylamine and amphetamine classes of drugs and is a sympathomimetic that accentuates catecholaminergic and serotonergic neurons \[[@C1]\]. Its precursor forms were initially used to treat asthma and sinus congestion (ephedrine) \[[@C2]\], and as a weight loss aid (fen-phen) \[[@C3]\]. The discovery of its stimulant effects in the early 20th century led to its widespread use as a performance-enhancer, then subsequently as a recreational drug of abuse in purified forms. Specifically, methamphetamine is sold illicitly as a powder or crystalline ("ice" or "crystal") form, intended for inhalation *via* smoking, the most common route of ingestion \[[@C1]\].

According to recent estimates \[[@C4]\] from 2012 in the United States, over 12 million people over the age of 12 years have used methamphetamine in their lifetimes, 1.2 million people reported having used in that past year, and 440 000 used it in that past month. According to the National Institute on Drug Abuse 2012 data, methamphetamine use was greatest in the western part of the United States and parts of the Midwest, and users were predominately White \[[@C5]\]. Outside of the United States, amphetamine-type stimulants, of which methamphetamine is the most common, are the second-most used class of illicit drugs worldwide \[[@C6]\]. Furthermore, the World Drug Report of 2013 estimates that methamphetamine use appears to be growing, further suggesting its use as a growing epidemic \[[@C7]\].

Because of the increased rates of methamphetamine use, there has been subsequent investigation into its toxic effects on health. In 2010, Volkow *et al*. \[[@C8]\] showed that the highest uptake of methamphetamine was in the lungs, liver, and kidney, suggesting its widespread organ distribution and potential for toxicity. Previously reported associations have been predominantly in the cardiac and respiratory systems, namely cardiomyopathy, acute coronary syndrome, and aortic dissection, as well as pulmonary arterial hypertension \[[@C9]--[@C11]\]. Small studies also exist to suggest the possible associations between methamphetamine use and barotrauma, cardiogenic pulmonary oedema, pulmonary haemorrhage, pulmonary granulomatosis, noncardiogenic pulmonary oedema, aspiration pneumonia, excessive bronchial reactivity, and hypersensitivity pneumonitis \[[@C12]\]. However, there is a paucity of investigation towards the scope of pulmonary toxicity that may be related to methamphetamine use.

Thus, the goal of this study was to determine whether methamphetamine use was associated with more hospitalisation codes for adults which capture four common pulmonary diseases: acute exacerbations of asthma, acute exacerbations of chronic obstructive pulmonary disease (COPD), pneumonia and acute respiratory failure. Our target of study focused on the data collected from California, a state that has been the focus of methamphetamine-related research in the past \[[@C13]\].

Materials and methods {#s2}
=====================

Study design and population {#s2a}
---------------------------

A retrospective observational study design was used to analyse California state inpatient databases (SIDs) obtained from the Healthcare Cost and Utilization Project (HCUP; [www.hcup-us.ahrq.gov/tech_assist/citations.jsp](www.hcup-us.ahrq.gov/tech_assist/citations.jsp)) from 2005 through 2011 for diagnosis of methamphetamine use and asthma exacerbation, COPD exacerbation, pneumonia and respiratory failure. Inpatient hospital discharges were included in the study population if patients were over 18 years old and were not missing data for key demographic variables (age, sex, estimated median household income of residents in the patient\'s ZIP code).

Outcomes {#s2b}
--------

Primary outcomes were discharge diagnoses of four common pulmonary diseases: acute exacerbations of asthma, COPD, pneumonia and acute respiratory failure. The relevant diagnoses were defined by International Classification of Diseases, Ninth Revision (ICD-9) codes documented in the top 10 diagnoses for each discharge ([table 1](#TB1){ref-type="table"}). Specific ICD-9 codes were chosen to capture discharge diagnoses of acute exacerbations of asthma and COPD, respiratory failure and diagnoses consistent with community-acquired pneumonia. Discharges with more than one of the diagnoses of interest were classified as having each of the diagnoses.

###### 

List of International Classification of Diseases (ninth revision) codes used to define exposures, outcomes and covariates

  **Diagnosis**                                     **Diagnosis code**                                                 **Description**
  ------------------------- ------------------------------------------------------------------ ---------------------------------------------------------------
  **Methamphetamine**                                     304.40                                Amphetamine and other psychostimulant dependence, unspecified
  304.41                       Amphetamine and other psychostimulant dependence, continuous    
  304.42                        Amphetamine and other psychostimulant dependence, episodic     
  305.70                     Amphetamine or related acting sympathomimetic abuse, unspecified  
  305.71                     Amphetamine or related acting sympathomimetic abuse, continuous   
  305.72                      Amphetamine or related acting sympathomimetic abuse, episodic    
  **Asthma**                                              493.01                                          Extrinsic asthma with status asthmaticus
  493.02                                Extrinsic asthma with (acute) exacerbation             
  493.11                                 Intrinsic asthma with status asthmaticus              
  493.12                                Intrinsic asthma with (acute) exacerbation             
  493.91                            Asthma, unspecified type, with status asthmaticus          
  493.92                           Asthma, unspecified type, with (acute) exacerbation         
  **COPD**                                                491.21                                  Obstructive chronic bronchitis with (acute) exacerbation
  491.22                           Obstructive chronic bronchitis with acute bronchitis        
  **Pneumonia**                                           481.0                                 Pneumococcal pneumonia (*Streptococcus pneumoniae* pneumonia)
  482.2                                 Pneumonia due to *Haemophilus influenzae*              
  482.30                              Pneumonia due to *Streptococcus*, unspecified            
  482.31                                Pneumonia due to *Streptococcus*, group A              
  482.32                                Pneumonia due to *Streptococcus*, group B              
  482.39                                  Pneumonia due to other *Streptococcus*               
  482.40                              Pneumonia due to *Staphylococcus*, unspecified           
  482.41                     Methicillin susceptible pneumonia due to *Staphylococcus aureus*  
  482.42                      Methicillin resistant pneumonia due to *Staphylococcus aureus*   
  482.49                                     Other *Staphylococcus* pneumonia                  
  482.84                                  Pneumonia due to Legionnaires' disease               
  483.0                                  Pneumonia due to *Mycoplasma pneumoniae*              
  **Respiratory failure**                                 518.81                                                  Acute respiratory failure
  **Tobacco**                                             305.1                                                     Tobacco use disorder
  989.84                                         Toxic effect of tobacco                       
  V15.82                                     Personal history of tobacco use                   
  **Cocaine**                                             304.20                                               Cocaine dependence, unspecified
  304.21                                      Cocaine dependence, continuous                   
  304.22                                       Cocaine dependence, episodic                    
  305.60                                        Cocaine abuse, unspecified                     
  305.61                                        Cocaine abuse, continuous                      
  305.62                                         Cocaine abuse, episodic                       

Independent variable and covariates {#s2c}
-----------------------------------

The exposure of interest was methamphetamine use (ICD-9 codes 304.40 to 304.42 and 305.70 to 305.72) in the top 10 diagnoses for each discharge. The selected methamphetamine use diagnoses included unspecified, continuous or episodic abuse or dependence. ICD-9 codes for patients in remission of methamphetamine abuse were excluded. In addition, we identified tobacco use (ICD-9 codes 305.1, 989.84, V15.82) as a possible confounder. The use of ICD-9 tobacco use codes for identifying smokers in a clinical population, while insensitive, has been supported in the literature \[[@C14]\]. Age, sex, race and median household income were used as demographic covariates. Age (18 to 25, 26 to 35, 36 to 45, 46 to 55, 56 to 65, 66 to 75 years) and race (White, Hispanic, other/missing) were grouped together for the analysis while sex and median household income quartiles \[[@C1]--[@C4]\] were used as documented in the database. On the basis of published demographic data, age ranges were centred above and below age 35 years, the median age of methamphetamine abusers, with a standard deviation of approximately 6 years and range from approximately age 20 to 70 years \[[@C13], [@C15]\].

Cocaine is also a sympathomimetic drug whose abuse has been documented to provoke and/or exacerbate the four lung diseases presented here \[[@C12], [@C16]--[@C20]\]. To serve as a comparison with a well-studied toxin, cocaine abuse and dependence (ICD-9 codes 304.20 to 304.22 and 305.60 to 305.62) in the top 10 diagnoses was considered as the exposure in sensitivity analyses.

Statistical analysis {#s2d}
--------------------

Rates of discharge diagnoses are presented as the number of discharges having that diagnosis in the numerator and the total number of discharges in the denominator.

Negative binomial regression models were used to estimate rate ratios (RR) with 95% confidence intervals (CIs) of pulmonary disease diagnoses between methamphetamine and nonmethamphetamine users. Models were adjusted for age group, race, median household income quartile and smoking. Given the known disparity in disease risk by sex \[[@C21]--[@C23]\], we fitted separate models for each pulmonary disease diagnosis by sex to estimate the RR of the disease in methamphetamine *versus* nonmethamphetamine users separately by sex. The same methods were applied in an analysis considering cocaine use as the exposure to provide a comparison with a well-studied toxin.

All statistical tests were performed at the 0.05 significance level and R \[[@C24]\] (version 3.3.1) was used for all analyses. The "MASS" \[[@C25]\] package (version 7.3--47) in R was used to fit the negative binomial regression models.

Results {#s3}
=======

Screening the California HCUP SID between 2005--2011 resulted in a total of 27 907 535 discharge abstracts that were available for analysis. Abstracts that reflected children (age \<18 years, n=5 594 831) or those with missing age (n=266 198) were excluded from further analysis. For the remaining abstracts, we excluded those with either missing sex (n=341 540), income (n=563 735) or both (n=15 982). This resulted in 21 125 249 discharge abstracts with complete demographic data for inclusion in our study, of which 182 766 carried a top-10 discharge diagnosis of methamphetamine abuse or dependence based on our inclusion criteria ([figure 1](#F1){ref-type="fig"}).

![Number of discharges included and excluded in analysis. HCUP: Healthcare Utilization Project; SID: state inpatient database; METH: methamphetamine.](00017-2019.01){#F1}

With regard to ethics approval and consent to participate, all the data used in the study were obtained from the HCUP database.

Demographics {#s3a}
------------

[Table 2](#TB2){ref-type="table"} summarises demographic data of the discharge diagnoses that were included in the study. The median age was 37 years (interquartile range (IQR) 28--47) in methamphetamine use discharges and 57 (IQR 37--75) for nonmethamphetamine use discharges. Methamphetamine use discharges tended to be male (n=106 665, 58%) compared with nonuse (n=7 982 930, 38%). A co-diagnosis of methamphetamine and tobacco use (n=68 312, 37%) occurred more frequently compared with diagnoses of tobacco use without methamphetamine use diagnosis (n=3 028 832, 14%). Rates of discharge diagnoses for both methamphetamine and nonmethamphetamine use in smokers and nonsmokers are presented by age and sex in [supplementary figure 1 and 2](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00017-2019.figures-only#fig-data-supplementary-materials).

###### 

California state inpatient database characteristics 2005--2011

                                                              **Meth discharges (n=182 766)**   **Nonmeth discharges (n=20 942 483)**   **SMD**
  ---------------------------------------------------------- --------------------------------- --------------------------------------- ---------
  **Age group**                                                                                                                          1.229
   18--25 years                                                        32 151 (18%)                        1 862 559 (8%)              
   26--35 years                                                        48 357 (26%)                        3 008 855 (14%)             
   36--45 years                                                        51 283 (28%)                        2 329 449 (11%)             
   46--55 years                                                        38 918 (21%)                        2 790 528 (13%)             
   56--65 years                                                         10 540 (6%)                        2 991 208 (14%)             
   66--75 years                                                          1517 (1%)                         7 959 884 (36%)             
  **Age years median (IQR)**                                            37 (28, 47)                          57 (37, 75)                 1.065
  **Sex**                                                                                                                                0.414
   Male                                                                106 665 (58%)                       7 982 930 (36%)             
   Female                                                              76 101 (42%)                       12 959 553 (59%)             
  **Race**                                                                                                                               0.127
   White                                                               104 846 (57%)                      11 150 306 (53%)             
   Hispanic                                                            46 532 (26%)                        5 186 339 (25%)             
   Black                                                                12 550 (7%)                        1 679 988 (8%)              
   Other/missing                                                       18 838 (10%)                        2 925 850 (14%)             
  **Median household income quartile by patient ZIP code**                                                                               0.279
   Quartile 1                                                          65 813 (36%)                        5 785 651 (26%)             
   Quartile 2                                                          53 387 (29%)                        5 312 536 (24%)             
   Quartile 3                                                          39 373 (22%)                        5 237 059 (24%)             
   Quartile 4                                                          24 193 (13%)                        4 607 237 (21%)             
  **Smoking**                                                          68 312 (37%)                        3 028 832 (14%)               0.542
  **Pulmonary disease diagnoses**                                                                                                      
   Asthma                                                                1076 (1%)                         106 712 (0.5%)                0.011
   COPD                                                                  2083 (1%)                          519 148 (2%)                 0.101
   Pneumonia                                                            898 (0.5%)                          99 947 (0.5%)                0.002
   Respiratory failure                                                   4031 (2%)                          463 840 (2%)                 0.001
   More than one of above                                               690 (0.4%)                          93 378 (0.4%)                0.01

Due to rounding, some percentages may not sum to 100%. Meth: methamphetamine; SMD: standardised mean difference; IQR: interquartile range.

![Rate ratio (RR) point estimates and 95% confidence intervals for each disease in methamphetamine *versus* nonmethamphetamine discharges for females and males. Models adjusted for race, median household income, age and smoking status. COPD: chronic obstructive pulmonary disease; PNA: pneumonia; RF: respiratory failure.](00017-2019.02){#F2}

Outcomes {#s3b}
--------

Discharges abstracts that included ICD-9 codes for methamphetamine use were 0.66 (95% CI 0.57, 0.77; p\<0.001) times as likely to have a simultaneous principal hospital discharge abstract for acute exacerbations of asthma compared with discharge abstracts without methamphetamine use in women and 0.71 (95% CI 0.61, 0.82; p\<0.001) times as likely in men ([figure 2](#F2){ref-type="fig"}). For COPD, the risk of having a principal hospital discharge abstract for acute exacerbations were 1.23 (95% CI 1.06, 1.42; p=0.01) times as likely in discharges with methamphetamine use *versus* nonmethamphetamine use in women and 0.90 (95% CI 0.79, 1.02; p=0.10) in men. We documented a RR for having a hospital discharge abstract for acute pneumonia in methamphetamine use *versus* nonmethamphetamine use of 1.40 (95% CI 1.18, 1.67; p\<0.001) in women and 1.18 (95% CI 1.04, 1.35; p=0.01) in men. Finally, the risk in methamphetamine use discharges of also having a discharge diagnosis of acute respiratory failure was 1.77 (95% CI 1.59, 1.98; p\<0.001) times the risk in nonmethamphetamine use discharges in women and 1.24 (95% CI 1.12, 1.37; p\<0.001) in men. Similar results were found when adjusted for a confounder of malnutrition, and results are presented in [Supplementary Figure 3](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00017-2019.figures-only#fig-data-supplementary-materials).

![Rate ratio (RR) point estimates and 95% confidence intervals (CI) for each disease in cocaine *versus* noncocaine discharges for females and males. Models adjusted for race, median household income, age, and smoking status. COPD: chronic obstructive pulmonary disease; PNA: pneumonia; RF: respiratory failure.](00017-2019.03){#F3}

Role of cocaine in discharge for lung diseases {#s3c}
----------------------------------------------

In our analysis, we found similarities between cocaine use and methamphetamine use discharges associated with each of the four lung diagnoses ([figure 3](#F3){ref-type="fig"}). In particular, we found a RR for asthma exacerbations of 0.87 (95% CI 0.75, 1.02; p=0.08) when comparing discharges with cocaine use *versus* discharges without cocaine use in men and 0.71 (95% CI 0.60, 0.83; p\<0.001) in women. Compared with discharges with methamphetamine use, the RR for COPD exacerbations in discharges with cocaine use was higher in women (RR: 2.46; 95% CI 2.11, 2.86; p\<0.001) and men (RR: 1.69; 95% CI 1.47, 1.94; p\<0.001). For pneumonia, discharges with cocaine use were 1.84 (95% CI 1.55, 2.20; p\<0.001) times as likely to have a pneumonia diagnosis compared with discharges without use in women and 0.88 (95% CI 0.76, 1.02; p=0.08) in men; for acute respiratory failure, the RR was 1.73 (95% CI 1.53, 1.95; p\<0.001) in women and 1.05 (95% CI 0.94, 1.16; p=0.39) in men.

Discussion {#s4}
==========

Our findings suggest that California inpatient hospitalisation discharge abstracts from the years 2005 through 2011 that include a code for methamphetamine use have an increased likelihood of also including a code for COPD exacerbation, acute pneumonia or acute respiratory failure when compared with discharge abstracts that do not include a code for methamphetamine use.

In our analysis, we found negative associations in both sexes between diagnosis codes for methamphetamine use and acute asthma exacerbation. This would suggest a decreased likelihood of concurrent discharge abstract diagnoses of methamphetamine use and acute asthma exacerbation that is contrary to our hypothesis that methamphetamine use may increase the risk of exacerbation. To our knowledge, there are no previously published data on the inhaled effects of methamphetamine with regards to airways diseases such as asthma. It is possible that this effect reflects a decreased likelihood for patients with concurrent discharge diagnoses to seek medical care, due to socioeconomic factors or mental health barriers that limit access to medical care. Another explanation for the RR being lower for asthma (and higher for COPD in women) may be that asthma is more commonly misdiagnosed as COPD in the presence of methamphetamine use. Finally, we acknowledge that the findings may reflect a limitation of the study design using ICD-9 codes as surrogates for exposure to methamphetamine and diagnosis of asthma exacerbation.

We identified a statistically significant positive association between diagnosis codes for methamphetamine use and acute COPD exacerbation in women. Surprisingly, there is scant literature regarding inhaled illicit drug use and rates of COPD exacerbation. While "crack" cocaine has been linked to increased risk of asthma exacerbations \[[@C26]\], most studies have failed to find inhaled marijuana to be a risk factor for development of COPD or increased rate of exacerbations \[[@C27]\]. To our knowledge, there are no published studies investigating a link between COPD and methamphetamine use. It is unclear why this positive association is seen in women but not is not statistically significant in men. In the original landmark TORCH COPD study, women did report more exacerbations and worse dyspnoea scores than men \[[@C22]\] thus, perhaps there was an increased propensity for women methamphetamine abusers to seek medical care for a concurrent COPD exacerbation.

The association between diagnosis codes for methamphetamine use and codes for the adverse pulmonary outcomes of COPD exacerbation, acute pneumonia or acute respiratory failure is in concordance with known pulmonary complications of acute respiratory failure related to another similar inhaled stimulant, "crack" cocaine \[[@C26]\]. Furthermore, there is some literature that describes a disruption by methamphetamine exposure on host immunity, placing methamphetamine users at increased risk for acquisition of diverse pathogens \[[@C28]\]. While much of the existing literature addresses increased rates of opportunistic infections and fungal infections such as histoplasmosis, methamphetamine has been reported to reduce T-cell infiltrates in the lungs, dampening the protective immune response against respiratory pathogens including community-acquired bacteria \[[@C29]\]. Also, the intoxicating effects of methamphetamine predisposes users to engage in risky behaviour and subsequently increases the risk of acquiring transmissible microbes or developing immunodeficiency (*e.g.* HIV and AIDS) \[[@C28]\]. Another interpretation of this association is the possibility that patients who are afflicted by substance abuse may have poorer access to general outpatient medical care, and in turn present to the hospital more acutely and would require inpatient stay for their acute illness.

Lastly, as the specific ICD-9 code for "acute respiratory failure" is broad, it may encompass all forms of respiratory failure, including pulmonary oedema (cardiogenic or noncardiogenic), acute respiratory distress syndrome or diffuse alveolar damage, all entities which have been linked to methamphetamine use in case reports \[[@C30]\]. It has been described during investigation of the link between methamphetamine use and pulmonary hypertension that methamphetamine exposure potentiates DNA damage in hypoxic cells, increasing mitochondrial reactive oxygen species \[[@C31]\]. As acute lung injury and acute respiratory distress syndrome have been shown to arise from free radical formation \[[@C32]\], it is possible that methamphetamine use *via* free radical formation may contribute to noncardiogenic pulmonary oedema and capillary leak \[[@C33]\].

Limitations to this study include that this was a retrospective study that used data collected from a database originally created for billing purposes. Because the database was not designed for the purpose of research, there was limited information available on potential confounders and some confounder data were missing. It is possible that the missingness differs by methamphetamine exposure. Other than adjusting for obvious confounders that were available information from the database, including malnutrition ([supplementary figure 3](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00017-2019.figures-only#fig-data-supplementary-materials)), there are probably other confounders that were not addressed (geographic location, domestic conditions, psychosocial environment, access to healthcare). This work presents several comparisons and the p-values should only be considered as descriptive measures that are not adjusted for the multiple tests performed. Additionally, by limiting our analysis to hospitalisation discharges, we cannot be certain whether the observed associations hold in the general population.

Furthermore, the use of ICD-9 codes as accurate surrogates for exposure (methamphetamine and tobacco) and disease state (asthma exacerbation, COPD exacerbation, pneumonia, respiratory failure) is dependent on the coders' accuracy in documenting the pertinent clinical problems for a given hospital discharge abstract. Misclassification is likely to attenuate the true RRs. Due to the nature of the dataset utilised, analysis was performed on discharge abstracts rather than on an individual basis because not all records could be linked to an individual. As a result, the temporality of the exposure is unknown in this study; for example, in the absence of urine toxicology data confirming methamphetamine exposure, a methamphetamine use ICD-9 code may still be documented based on history of use.

Future directions of investigation include validating this research question in the general population and further stratifying those with simultaneous diagnoses of methamphetamine use and community-acquired pneumonia by co-diagnosis of immunocompromised state such as HIV or AIDS based on proposed mechanisms of methamphetamine and infectious diseases. Many of the discharge abstracts available in the dataset are those of the oldest patients. Future research should evaluate whether the associations observed here vary by age. Furthermore, as recreational methamphetamine production has become purer over time \[[@C34]\], an analysis stratified by year of discharge may provide insight into changes in the relationship between methamphetamine use and lung disease over time.

Conclusion {#s4a}
----------

When adjusted for age, race, economic quartile and tobacco smoking, discharge diagnoses with methamphetamine use diagnoses are associated with higher rates of concurrent diagnoses of community-acquired pneumonia and acute respiratory failure among men and women, and acute COPD exacerbation among women when compared with those with no methamphetamine use diagnosis. Further investigation is necessary to elucidate a potential mechanism on how methamphetamine use leads to development of these common pulmonary diagnoses. We hope that this study brings awareness to the growing methamphetamine epidemic and its potential for lung injury beyond the pulmonary vasculature and the cardiopulmonary system, namely the airways and lung parenchyma. Lastly, there is also potential for further investigation with regards to the healthcare cost of the methamphetamine epidemic and utilisation of services of the healthcare system.
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